{
  "company": "Quidel Corporation",
  "ticker": "QDEL",
  "period": {
    "from": "2026-03-23",
    "to": "2026-04-22",
    "days": 30
  },
  "sentiment_breakdown": {
    "positive": 22,
    "negative": 20,
    "neutral": 16
  },
  "synthesis": {
    "executive_summary": "Sentiment analysis for Quidel Corporation (QDEL) from 2026-03-23 to 2026-04-22. Analyzed 58 items across FDA and news sources.",
    "key_findings": [],
    "overall_sentiment": "neutral"
  },
  "top_positive": [
    {
      "title": "The safety, reactogenicity, and immunogenicity of the self-amplifying mRNA COVID-19 vaccine GRT-R910 as a booster in healthy adults.",
      "date": "2026 Apr 2",
      "source": "pubmed",
      "score": 0.67
    },
    {
      "title": "QuidelOrtho Corp. Opens with 5.51% Gain Amid Ongoing Financial Challenges",
      "date": "2026-04-16",
      "source": "alpha_vantage",
      "score": 0.572
    },
    {
      "title": "QuidelOrtho Completes $100 Million Acquisition of LEX Diagnostics to Expand Rapid Molecular Testing",
      "date": "2026-04-20",
      "source": "alpha_vantage",
      "score": 0.518
    },
    {
      "title": "QuidelOrtho: $100 Million Acquisition Of LEX Diagnostics Completed To Expand Ultra-Fast PCR Testing",
      "date": "2026-04-20",
      "source": "alpha_vantage",
      "score": 0.518
    },
    {
      "title": "QuidelOrtho (QDEL) Welcomes New Chief Legal Officer",
      "date": "2026-03-25",
      "source": "alpha_vantage",
      "score": 0.494
    },
    {
      "title": "Diagnosis of Cardiac Amyloidosis on Echocardiography Using Artificial Intelligence.",
      "date": "2026-04-22",
      "source": "pubmed",
      "score": 0.477
    },
    {
      "title": "QuidelOrtho, Lifotronic Technology to Expand Global Immunoassay Portfolio",
      "date": "2026-04-10",
      "source": "alpha_vantage",
      "score": 0.318
    },
    {
      "title": "QuidelOrtho Corp (QDEL) Shares Surge 7.7% -- What GF Score of 63 Tells Investors",
      "date": "2026-04-14",
      "source": "alpha_vantage",
      "score": 0.296
    },
    {
      "title": "Is It Time To Reassess QuidelOrtho (QDEL) After The Recent Share Price Slump?",
      "date": "2026-04-08",
      "source": "alpha_vantage",
      "score": 0.296
    },
    {
      "title": "Is It Time To Reassess QuidelOrtho (QDEL) After The Recent Share Price Slump?",
      "date": "2026-04-07",
      "source": "alpha_vantage",
      "score": 0.296
    }
  ],
  "top_negative": [
    {
      "title": "Weaker flu season weighs on QuidelOrtho as Q1 sales fall below $620M",
      "date": "2026-04-15",
      "source": "alpha_vantage",
      "score": -0.67
    },
    {
      "title": "QuidelOrtho (QDEL) Valuation Check After Weaker Q1 2026 Revenue Guidance And Sharply Negative Share Returns",
      "date": "2026-04-16",
      "source": "alpha_vantage",
      "score": -0.66
    },
    {
      "title": "QuidelOrtho (QDEL) Projects Lower Q1 2026 Revenue Amid Weaker De",
      "date": "2026-04-15",
      "source": "alpha_vantage",
      "score": -0.625
    },
    {
      "title": "UBS cuts Quidel stock price target on weaker respiratory season",
      "date": "2026-04-11",
      "source": "alpha_vantage",
      "score": -0.625
    },
    {
      "title": "UBS cuts Quidel stock price target on weaker respiratory season",
      "date": "2026-04-10",
      "source": "alpha_vantage",
      "score": -0.625
    },
    {
      "title": "EMPEROR-Preserved Risk Model and Outcomes in the FINEARTS-HF Trial: A Prespecified Secondary Analysis of FINEARTS-HF.",
      "date": "2026 Mar 2",
      "source": "pubmed",
      "score": -0.473
    },
    {
      "title": "QuidelOrtho Corp. Faces Weak Start with 13.49% Gap Down Amid Market Concerns",
      "date": "2026-04-18",
      "source": "alpha_vantage",
      "score": -0.44
    },
    {
      "title": "QuidelOrtho stock plunges on weak revenue guidance",
      "date": "2026-04-15",
      "source": "alpha_vantage",
      "score": -0.44
    },
    {
      "title": "QuidelOrtho stock plunges on weak revenue guidance By Investing.com",
      "date": "2026-04-15",
      "source": "alpha_vantage",
      "score": -0.44
    },
    {
      "title": "QuidelOrtho (QDEL) Is Down 18.0% After Proposed NIH Funding Cuts Raised Diagnostics Demand Questions",
      "date": "2026-04-10",
      "source": "alpha_vantage",
      "score": -0.402
    }
  ],
  "raw_data": {
    "total_items": 58,
    "items": [
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho completes LEX Diagnostics buy for $100 million By Investing.com",
        "url": "https://in.investing.com/news/company-news/quidelortho-completes-lex-diagnostics-buy-for-100-million-93CH-5345868",
        "date": "2026-04-21",
        "summary": "QuidelOrtho Corporation has announced the completion of its acquisition of LEX Diagnostics for approximately $100 million in cash. This acquisition adds the LEX VELO System, a molecular diagnostics platform providing rapid testing for Influenza A, B, and COVID-19, enhancing QuidelOrtho's molecular diagnostics portfolio. Despite the strategic acquisition, QuidelOrtho's stock has declined, and the company recently preannounced weaker-than-expected first-quarter results due to a soft respiratory se",
        "sentiment_score": 0.191352,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho acquires molecular diagnostics firm LEX Diagnostics By Investing.com",
        "url": "https://za.investing.com/news/company-news/quidelortho-acquires-molecular-diagnostics-firm-lex-diagnostics-93CH-4220138",
        "date": "2026-04-20",
        "summary": "QuidelOrtho has acquired LEX Diagnostics Limited, a UK-based molecular diagnostics company known for its rapid point-of-care PCR testing platform, VELO system. The acquisition occurs while QuidelOrtho's stock is near its 52-week low, but analysts anticipate a return to profitability this year. The VELO system, cleared by the FDA, offers quick PCR results for common respiratory infections, expanding QuidelOrtho's diagnostics portfolio.",
        "sentiment_score": -0.126871,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "TTP Group announces sale of LEX Diagnostics to QuidelOrtho",
        "url": "https://www.tipranks.com/news/the-fly/ttp-group-announces-sale-of-lex-diagnostics-to-quidelortho-thefly-news",
        "date": "2026-04-20",
        "summary": "TTP Group has announced the sale of LEX Diagnostics, a UK-based molecular diagnostics company, to QuidelOrtho (QDEL). LEX Diagnostics, a spin-out of TTP, developed a point-of-care molecular testing platform, the VELO system, which delivers PCR results for Flu A, Flu B, and COVID-19 in minutes. The VELO system received U.S. Food and Drug Administration 510(k) clearance and CLIA waived status in February 2026, enabling rapid diagnosis and quicker clinical decisions.",
        "sentiment_score": 0.427387,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho Completes $100 Million Acquisition of LEX Diagnostics to Expand Rapid Molecular Testing",
        "url": "https://www.citybiz.co/article/834221/quidelortho-completes-100-million-acquisition-of-lex-diagnostics-to-expand-rapid-molecular-testing/",
        "date": "2026-04-20",
        "summary": "QuidelOrtho has acquired LEX Diagnostics for approximately $100 million, enhancing its rapid molecular testing capabilities. This acquisition includes the FDA-cleared LEX VELO System, a platform that provides multiplex RT-PCR results for Influenza A, B, and COVID-19 in minutes, suitable for point-of-care settings. The move aims to diversify QuidelOrtho's diagnostics portfolio and strengthen its position in the growing market for near-patient testing.",
        "sentiment_score": 0.435472,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.518,
          "confidence": 0.52
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho Completes Acquisition of LEX Diagnostics and Molecular Testing Platform",
        "url": "https://clpmag.com/lab-management/company-news/quidelortho-acquires-lex-diagnostics-molecular-testing-platform/",
        "date": "2026-04-20",
        "summary": "QuidelOrtho Corp has finalized its acquisition of LEX Diagnostics for approximately $100 million in cash. This deal brings the LEX VELO System, an ultra-fast molecular diagnostics platform cleared by the FDA for Influenza A, Influenza B, and COVID-19 testing, into QuidelOrtho's point-of-care portfolio. The acquisition aims to accelerate QuidelOrtho’s growth in the point-of-care molecular diagnostics market and support rapid clinical decision-making.",
        "sentiment_score": 0.84978,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho: $100 Million Acquisition Of LEX Diagnostics Completed To Expand Ultra-Fast PCR Testing",
        "url": "https://pulse2.com/quidelortho-100-million-acquisition-of-lex-diagnostics-completed-to-expand-ultra-fast-pcr-testing/amp/",
        "date": "2026-04-20",
        "summary": "QuidelOrtho Corporation has acquired LEX Diagnostics for approximately $100 million, enhancing its point-of-care molecular diagnostics portfolio with the LEX VELO System. This ultra-fast RT-PCR platform provides rapid results for Influenza A, B, and COVID-19, having recently received FDA 510(k) clearance and CLIA waiver. The acquisition aims to expand QuidelOrtho's molecular diagnostics capabilities and improve patient outcomes through faster clinical decision-making.",
        "sentiment_score": 0.457983,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.518,
          "confidence": 0.52
        }
      },
      {
        "source": "alpha_vantage",
        "title": "PCR results in 6 minutes: QuidelOrtho buys LEX Diagnostics",
        "url": "https://www.stocktitan.net/news/QDEL/ttp-group-announces-the-sale-of-lex-c52urvzjl5f7.html",
        "date": "2026-04-20",
        "summary": "QuidelOrtho Corporation has acquired LEX Diagnostics Limited, a UK-based molecular diagnostics company spun out of TTP Group. LEX Diagnostics is known for its VELO system, which provides ultra-fast, lab-quality PCR results for Flu A, Flu B, and COVID-19 in minutes, and recently received FDA 510(k) clearance and CLIA waived status. This acquisition enhances QuidelOrtho's point-of-care diagnostics capabilities, allowing for faster diagnoses and clinical decisions.",
        "sentiment_score": 0.474355,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "10-minute flu and COVID PCR test joins QuidelOrtho in $100M deal",
        "url": "https://www.stocktitan.net/news/QDEL/quidel-ortho-corporation-completes-acquisition-of-lex-ikimvhxfv4is.html",
        "date": "2026-04-20",
        "summary": "QuidelOrtho has successfully acquired LEX Diagnostics for approximately $100 million, integrating the FDA-cleared and CLIA-waived LEX VELO System into its molecular diagnostics portfolio. This rapid PCR platform delivers multiplex Influenza A/B and COVID-19 results within 6-10 minutes. The acquisition aims to expand QuidelOrtho's point-of-care offerings, with a U.S. commercial launch anticipated later in 2026.",
        "sentiment_score": 0.271834,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 0.993856,
        "sentiment": {
          "label": "negative",
          "score": -0.382,
          "confidence": 0.38
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho Corporation Completes Acquisition of LEX Diagnostics",
        "url": "https://www.prnewswire.com/news-releases/quidelortho-corporation-completes-acquisition-of-lex-diagnostics-302746364.html",
        "date": "2026-04-20",
        "summary": "QuidelOrtho Corporation announced the completion of its acquisition of LEX Diagnostics for approximately $100 million, marking a significant step in accelerating its growth in point-of-care molecular diagnostics. This acquisition integrates LEX's VELO System, an ultra-fast PCR platform that provides rapid diagnostic results, into QuidelOrtho's portfolio. The LEX VELO System received FDA 510(k) clearance and CLIA waiver in February 2026, with a U.S. commercial launch anticipated later this year.",
        "sentiment_score": 0.478686,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho Corp. Faces Weak Start with 13.49% Gap Down Amid Market Concerns",
        "url": "https://www.marketsmojo.com/news/stocks-in-action/quidelortho-corp-faces-weak-start-with-1349-gap-down-amid-market-concerns-3911050",
        "date": "2026-04-18",
        "summary": "QuidelOrtho Corp. stock experienced a significant 13.49% gap down, contributing to a 20.29% daily drop and a 36.92% monthly decrease. Technical indicators signal a bearish outlook for the company, which operates in the Pharmaceuticals & Biotechnology sector. Financial metrics show a market capitalization of USD 1,202 million, a debt-to-equity ratio of 1.31, and a negative return on equity of -7.95%.",
        "sentiment_score": -0.803637,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.44,
          "confidence": 0.44
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho preliminary revenue to hit USD 615-620M in Q1 2026",
        "url": "https://medicalbuyer.co.in/quidelortho-preliminary-revenue-to-hit-usd-615-620m-in-q1-2026/",
        "date": "2026-04-18",
        "summary": "QuidelOrtho announced preliminary unaudited revenue of $615-$620 million for Q1 2026, below expectations due to a weaker respiratory season, slower China distributor sales, and delayed EMEA orders from the Middle East conflict. Despite these challenges, CEO Brian J. Blaser stated the company is taking cost actions and its core business remains strong. The company expects negative free cash flow for H1 2026, but projects positive free cash flow for the full year.",
        "sentiment_score": -0.316059,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "J.P. Morgan Maintains QuidelOrtho(QDEL.US) With Sell Rating, Cuts Target Price to $15",
        "url": "https://www.moomoo.com/news/post/68459654/jp-morgan-maintains-quidelortho-qdelus-with-sell-rating-cuts-target",
        "date": "2026-04-17",
        "summary": "J.P. Morgan has reiterated its Sell rating on QuidelOrtho (QDEL.US) and reduced its price target for the stock to $15. This adjustment follows a review of the company's financial outlook and market position.",
        "sentiment_score": -0.446742,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho Corp (QDEL) Stock Down 27.5% -- Now Undervalued? GF Score: 61/100",
        "url": "https://www.gurufocus.com/news/8799678/quidelortho-corp-qdel-stock-down-275-now-undervalued-gf-score-61100?mobile=true",
        "date": "2026-04-17",
        "summary": "QuidelOrtho Corp (QDEL) shares dropped 27.5% on April 16, 2026, closing at $12.69, leading to a year-to-date decline of 55.6%. Despite this, GuruFocus's GF Value™ suggests the stock is 68.1% undervalued at $39.79, indicating a \"Possible Value Trap.\" Insiders have purchased $0.6 million worth of shares, reflecting confidence, but the company's financial strength and valuation ranks suggest investors should proceed with caution and conduct further research.",
        "sentiment_score": 0.254391,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho (QDEL) Valuation Check After Weaker Q1 2026 Revenue Guidance And Sharply Negative Share Returns",
        "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-qdel/quidelortho/news/quidelortho-qdel-valuation-check-after-weaker-q1-2026-revenu/amp",
        "date": "2026-04-16",
        "summary": "QuidelOrtho (QDEL) recently issued weaker Q1 2026 revenue guidance of US$615 million to US$620 million due to various market challenges. This news has led to sharply negative share returns, with the stock experiencing significant drops over the past day, 90 days, and year. Despite these headwinds, Simply Wall St's analysis suggests QDEL is currently undervalued, with a fair value pegged at $34.67 per share compared to its recent trading price of US$12.69.",
        "sentiment_score": -0.414535,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho Corp. Opens with 5.51% Gain Amid Ongoing Financial Challenges",
        "url": "https://www.marketsmojo.com/news/stocks-in-action/quidelortho-corp-opens-with-551-gain-amid-ongoing-financial-challenges-3911490",
        "date": "2026-04-16",
        "summary": "QuidelOrtho Corp. saw a 5.51% gain today, contrasting with a significant 56.32% decline over the past year. Despite this momentary uplift, the company continues to face severe financial challenges, including a high debt-equity ratio of 138.72% and 12 consecutive quarters of negative results. Technical indicators show a mixed picture, with weekly MACD bearish but monthly signals mildly bullish, yet the company consistently underperforms its benchmark.",
        "sentiment_score": -0.270146,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.572,
          "confidence": 0.57
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho (NASDAQ:QDEL) Sets New 1-Year Low - Here's What Happened",
        "url": "https://www.marketbeat.com/instant-alerts/quidelortho-nasdaqqdel-sets-new-1-year-low-heres-what-happened-2026-04-16/",
        "date": "2026-04-16",
        "summary": "QuidelOrtho (NASDAQ:QDEL) stock hit a new 52-week low of $12.32, closing at $11.7370 on heavy volume, following a prior close of $17.49. Analyst sentiment has largely turned negative, with several downgrades and price target cuts, although the company slightly beat quarterly revenue and EPS estimates. Despite a negative net margin and P/E, recent insider transactions show both a director and the CFO acquiring additional shares.",
        "sentiment_score": -0.726438,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.273,
          "confidence": 0.27
        }
      },
      {
        "source": "alpha_vantage",
        "title": "William Blair Maintains QuidelOrtho(QDEL.US) With Hold Rating",
        "url": "https://www.moomoo.com/news/post/68402102/william-blair-maintains-quidelortho-qdelus-with-hold-rating",
        "date": "2026-04-16",
        "summary": "William Blair has reiterated its Hold rating on QuidelOrtho (QDEL.US). This action indicates the firm's current neutral stance on the company's stock, suggesting investors should neither buy nor sell shares at this time.",
        "sentiment_score": 0.021667,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho Shares Plunge 20% After Weak Q1 Outlook",
        "url": "https://nationaltoday.com/us/ca/san-diego/news/2026/04/16/quidelortho-shares-plunge-20-after-weak-q1-outlook/",
        "date": "2026-04-16",
        "summary": "QuidelOrtho's stock plunged over 20% after reporting preliminary Q1 2026 revenue far below expectations, citing a weaker respiratory season, slow China sales, and EMEA order delays. The diagnostic healthcare company also anticipates negative free cash flow for the first half of 2026. This performance is seen as an indicator of broader industry challenges impacting public health monitoring and medical supply chains.",
        "sentiment_score": -0.719405,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.178,
          "confidence": 0.18
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho (QDEL) Projects Lower Q1 2026 Revenue Amid Weaker De",
        "url": "https://www.gurufocus.com/news/8795982/quidelortho-qdel-projects-lower-q1-2026-revenue-amid-weaker-demand",
        "date": "2026-04-15",
        "summary": "QuidelOrtho (QDEL) announced an expected preliminary revenue of $617.5 million for Q1 2026, driven by a diminished respiratory season and reduced sales in China, leading to an 11% decline in after-hours trading. The company also anticipates negative free cash flow. Despite insider buying activity, the moderate GF Score and financial vulnerabilities suggest caution for investors.",
        "sentiment_score": -0.610327,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.625,
          "confidence": 0.62
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho (QDEL) Drops 20% After-Hours On Wednesday— What's Going On?",
        "url": "https://www.sahmcapital.com/news/content/quidelortho-qdel-drops-20-after-hours-on-wednesday-whats-going-on-2026-04-16",
        "date": "2026-04-15",
        "summary": "QuidelOrtho (QDEL) saw a 20% drop in after-hours trading after releasing preliminary first-quarter 2026 revenue figures that were lower than expected. The company attributed the weak performance to a mild respiratory season, decreased U.S. Influenza-like Illness visits, slower China distributor sales, and delays in EMEA orders. Despite projecting negative free cash flow for the first half of 2026, QuidelOrtho maintains expectations for positive free cash flow for the full year.",
        "sentiment_score": -0.423587,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho stock plunges on weak revenue guidance",
        "url": "https://m.investing.com/news/stock-market-news/quidelortho-stock-plunges-on-weak-revenue-guidance-93CH-4616548?ampMode=1",
        "date": "2026-04-15",
        "summary": "QuidelOrtho Corporation (NASDAQ:QDEL) shares dropped significantly after issuing preliminary first-quarter 2026 revenue guidance well below Wall Street estimates. The company attributed the shortfall to a weak respiratory season, slower distributor sales in China due to proposed reimbursement rate reductions, and delayed orders in EMEA from the Middle East conflict. Despite a strong core business, the company anticipates negative free cash flow for Q1 2026 and is implementing cost reduction meas",
        "sentiment_score": -0.420352,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.44,
          "confidence": 0.44
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho stock plunges on weak revenue guidance By Investing.com",
        "url": "https://m.au.investing.com/news/stock-market-news/quidelortho-stock-plunges-on-weak-revenue-guidance-93CH-4364918?ampMode=1",
        "date": "2026-04-15",
        "summary": "QuidelOrtho Corporation's shares plunged 21% after hours due to weak preliminary first-quarter 2026 revenue guidance, significantly missing Wall Street estimates. The company cited a weaker respiratory season, slower distributor sales in China, and delayed orders in EMEA due to the Middle East conflict as main reasons. Despite these challenges, the CEO noted that the core business remains strong, and cost reduction measures are being implemented.",
        "sentiment_score": -0.708685,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.44,
          "confidence": 0.44
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho (NASDAQ: QDEL) guides Q1 revenue $615–620M with negative free cash flow",
        "url": "https://www.stocktitan.net/sec-filings/QDEL/8-k-quidel-ortho-corp-reports-material-event-30eb0ec60a04.html",
        "date": "2026-04-15",
        "summary": "QuidelOrtho announced preliminary unaudited Q1 2026 revenue of $615–$620 million, attributing the lower figures to a weaker respiratory season, slower sales in China due to proposed reimbursement cuts, and EMEA order delays from the Middle East conflict. The company expects negative free cash flow of $(65) to $(70) million for Q1 2026 but anticipates positive free cash flow for the full year. Despite these challenges, QuidelOrtho believes the low end of its full-year 2026 financial guidance rema",
        "sentiment_score": -0.202214,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.103,
          "confidence": 0.1
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho reports preliminary Q1 2026 revenue of $615-620 million",
        "url": "https://www.streetinsider.com/Corporate+News/QuidelOrtho+reports+preliminary+Q1+2026+revenue+of+%24615-620+million/26318717.html",
        "date": "2026-04-15",
        "summary": "QuidelOrtho (NASDAQ: QDEL) announced preliminary unaudited revenue of $615-620 million for the first quarter of 2026, a figure impacted by a weaker respiratory season and slower international sales. Despite these macroeconomic challenges, the company's CEO, Brian J. Blaser, stated that the core business remains strong, and QuidelOrtho is taking cost actions to drive full-year performance. The company expects negative free cash flow for Q1 and H1 2026 but maintains its full-year positive free cas",
        "sentiment_score": -0.217525,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Weaker flu season weighs on QuidelOrtho as Q1 sales fall below $620M",
        "url": "https://www.stocktitan.net/news/QDEL/quidel-ortho-announces-preliminary-revenue-for-the-first-quarter-hnu4csxonoca.html",
        "date": "2026-04-15",
        "summary": "QuidelOrtho announced preliminary unaudited Q1 2026 revenue of $615-$620 million, attributing the lower figures to a weaker respiratory season, slower China distributor sales, and delayed EMEA orders due to ongoing conflicts. Despite an expected negative free cash flow for Q1 2026, the company maintains that the low end of its full-year 2026 financial guidance is still achievable. Full financial results for Q1 2026 are scheduled for release on May 5, 2026.",
        "sentiment_score": -0.396003,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.67,
          "confidence": 0.67
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho Corp. Stock Plummets to New 52-Week Low at $14.00",
        "url": "https://www.marketsmojo.com/news/stocks-in-action/quidelortho-corp-stock-plummets-to-new-52-week-low-at-1400-3946035",
        "date": "2026-04-15",
        "summary": "QuidelOrtho Corp. has hit a new 52-week low of $14.00, marking a significant 65.59% stock price decline over the past year. The company, a small-cap player in the Pharmaceuticals & Biotechnology sector, has reported negative results for 12 consecutive quarters, along with a high debt-equity ratio and no dividends. These financial metrics and persistent operational struggles raise concerns about its future viability, especially when contrasted with the S&P 500's performance.",
        "sentiment_score": -0.911433,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.273,
          "confidence": 0.27
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho Corp (QDEL) Shares Surge 7.7% -- What GF Score of 63 Tells Investors",
        "url": "https://www.gurufocus.com/news/8793607/quidelortho-corp-qdel-shares-surge-77-what-gf-score-of-63-tells-investors",
        "date": "2026-04-14",
        "summary": "QuidelOrtho Corp (QDEL) shares surged 7.7% to $17.32, marking a significant daily gain despite a year-long decline from its 52-week high. The stock is considered undervalued by GuruFocus's GF Value™ with a 56.5% upside, though a low valuation score and historical P/E suggest potential for a \"value trap.\" Insider buying of $0.6 million in the last three months indicates executive confidence in the company's future prospects.",
        "sentiment_score": 0.205981,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "UBS cuts Quidel stock price target on weaker respiratory season",
        "url": "https://www.investing.com/news/analyst-ratings/ubs-cuts-quidel-stock-price-target-on-weaker-respiratory-season-93CH-4608139",
        "date": "2026-04-11",
        "summary": "UBS has lowered its price target for Quidel Corp. (NASDAQ:QDEL) to $17 from $30, while maintaining a Neutral rating, due to an anticipated weaker respiratory season. The stock is currently trading near its 52-week low, and analyst targets range from $25 to $50. Despite mixed Q4 2025 earnings and a significant year-to-date decline, UBS notes that much of the negative news regarding China diagnostics is already priced into the stock.",
        "sentiment_score": -0.28922,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.625,
          "confidence": 0.62
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho, Lifotronic Technology to Expand Global Immunoassay Portfolio",
        "url": "https://www.mpo-mag.com/breaking-news/quidelortho-lifotronic-technology-to-expand-global-immunoassay-portfolio/",
        "date": "2026-04-10",
        "summary": "QuidelOrtho has formed a long-term strategic supply agreement with Lifotronic Technology Co. Ltd. to enhance its global immunoassay portfolio. This collaboration will provide QuidelOrtho access to new high-throughput and low-to-mid volume immunoassay analyzer platforms and more than 25 new assays, expanding its offerings in key international markets outside the United States. The partnership aims to deliver scalable, cost-efficient diagnostic solutions and increase competitiveness in internation",
        "sentiment_score": 0.447653,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.318,
          "confidence": 0.32
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho (QDEL) Is Down 18.0% After Proposed NIH Funding Cuts Raised Diagnostics Demand Questions",
        "url": "https://www.sahmcapital.com/news/content/quidelortho-qdel-is-down-180-after-proposed-nih-funding-cuts-raised-diagnostics-demand-questions-2026-04-10",
        "date": "2026-04-10",
        "summary": "QuidelOrtho (QDEL) shares dropped 18.0% following news of a proposed US$5.00 billion reduction in funding for the National Institutes of Health, intensifying concerns about demand for diagnostic solutions. This adds to existing pressures on the company, which is already grappling with declining COVID testing revenues and restructuring challenges. While analysts maintain a \"Hold\" rating, the market reaction underscores the sensitivity of healthcare funding policy to investor sentiment, despite no",
        "sentiment_score": -0.440251,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.402,
          "confidence": 0.4
        }
      },
      {
        "source": "alpha_vantage",
        "title": "UBS cuts Quidel stock price target on weaker respiratory season",
        "url": "https://m.uk.investing.com/news/stock-market-news/ubs-cuts-quidel-stock-price-target-on-weaker-respiratory-season-93CH-4602756?ampMode=1",
        "date": "2026-04-10",
        "summary": "UBS has lowered its price target for Quidel Corp. (NASDAQ:QDEL) to $17 from $30, while maintaining a Neutral rating, due to an anticipated weaker respiratory season. The firm revised its estimates ahead of Q1 earnings, noting that much of the negative news regarding China diagnostics is already factored into the stock's recent 53% decline. Investor focus remains on Quidel's non-respiratory business growth, China diagnostics, and free cash flow visibility.",
        "sentiment_score": -0.306887,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.625,
          "confidence": 0.62
        }
      },
      {
        "source": "alpha_vantage",
        "title": "UBS Adjusts Price Target on QuidelOrtho to $17 From $30, Maintains Neutral Rating",
        "url": "https://www.marketscreener.com/news/ubs-adjusts-price-target-on-quidelortho-to-17-from-30-maintains-neutral-rating-ce7e50d9d98ef12d",
        "date": "2026-04-10",
        "summary": "UBS has significantly lowered its price target for QuidelOrtho (QDEL) to $17 from $30, while continuing to maintain a Neutral rating on the stock. This adjustment comes after QuidelOrtho announced its Q4 2025 earnings, which saw a decline in earnings despite a rise in revenue. The company also provided guidance for its fiscal year 2026.",
        "sentiment_score": -0.221429,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "UBS Maintains QuidelOrtho(QDEL.US) With Hold Rating, Cuts Target Price to $17",
        "url": "https://www.moomoo.com/news/post/68158826/ubs-maintains-quidelortho-qdelus-with-hold-rating-cuts-target-price",
        "date": "2026-04-10",
        "summary": "UBS has reiterated its Hold rating on QuidelOrtho (QDEL.US) but has lowered its target price for the stock to $17. This adjustment reflects an updated outlook from the firm regarding the company's financial prospects.",
        "sentiment_score": -0.273068,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho (QDEL) Is Down 18.0% After Proposed NIH Funding Cuts Raised Diagnostics Demand Questions",
        "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-qdel/quidelortho/news/quidelortho-qdel-is-down-180-after-proposed-nih-funding-cuts",
        "date": "2026-04-09",
        "summary": "QuidelOrtho's stock dropped 18.0% following a proposed US federal budget for 2027 that includes a US$5.00 billion cut to the National Institutes of Health. This news has intensified concerns about future research funding in healthcare, adding uncertainty to the diagnostics market. Despite the stock decline, analysts' price targets remain above the current price, indicating that the fundamental outlook hasn't drastically changed, though market sentiment is highly sensitive to policy shifts regard",
        "sentiment_score": -0.400285,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.402,
          "confidence": 0.4
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Is It Time To Reassess QuidelOrtho (QDEL) After The Recent Share Price Slump?",
        "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-qdel/quidelortho/news/is-it-time-to-reassess-quidelortho-qdel-after-the-recent-sha",
        "date": "2026-04-08",
        "summary": "This article examines QuidelOrtho (QDEL) after a significant share price decline, finding it undervalued according to Discounted Cash Flow (DCF) and Price/Sales (P/S) analyses. The DCF model suggests an intrinsic value of US$80.65 per share, indicating an 80.3% undervaluation compared to its current price of US$15.88. Additionally, its P/S ratio of 0.40x is well below industry averages and its proprietary Fair Ratio, further suggesting undervaluation.",
        "sentiment_score": 0.294579,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Is It Time To Reassess QuidelOrtho (QDEL) After The Recent Share Price Slump?",
        "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-qdel/quidelortho/news/is-it-time-to-reassess-quidelortho-qdel-after-the-recent-sha/amp",
        "date": "2026-04-07",
        "summary": "QuidelOrtho (QDEL) has experienced significant share price declines over various periods, prompting a reassessment of its valuation. A Discounted Cash Flow (DCF) analysis suggests the stock is currently 80.3% undervalued, with an intrinsic value of US$80.65 per share against a recent price of US$15.88. Additionally, its Price-to-Sales (P/S) ratio of 0.40x is significantly below the industry average and Simply Wall St's Fair Ratio, also indicating undervaluation.",
        "sentiment_score": 0.436772,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho Corp (QDEL) Trading Down 5.04% on Apr 6",
        "url": "https://www.gurufocus.com/news/8776422/quidelortho-corp-qdel-trading-down-504-on-apr-6?mobile=true",
        "date": "2026-04-06",
        "summary": "QuidelOrtho Corp (QDEL) shares fell 5.04% on April 6th, reaching an intraday low of $16.20 before closing at $16.38. This places the stock significantly below its 52-week high but above its 52-week low. Wall Street analysts and GuruFocus estimate a substantial upside for QDEL, with average price targets suggesting a \"Hold\" recommendation.",
        "sentiment_score": -0.249339,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho (NASDAQ:QDEL) Rating Increased to Buy at Wall Street Zen",
        "url": "https://www.marketbeat.com/instant-alerts/quidelortho-nasdaqqdel-rating-increased-to-buy-at-wall-street-zen-2026-04-04/",
        "date": "2026-04-04",
        "summary": "Wall Street Zen has upgraded QuidelOrtho (NASDAQ:QDEL) from \"hold\" to \"buy,\" despite a mixed consensus from other analysts, resulting in an average \"Reduce\" rating and a $31.50 price target. The company recently surpassed quarterly earnings and revenue estimates, reporting $0.46 EPS and $723.6M revenue. Additionally, insider buying activity by the CFO and a director suggests confidence, with significant share purchases totaling approximately $568k.",
        "sentiment_score": 0.133846,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.273,
          "confidence": 0.27
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho Corp Stock: Navigating Diagnostics Leadership Amid Sector Evolution and Investor Opportu",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/quidelortho-corp-stock-navigating-diagnostics-leadership-amid-sector/69047279",
        "date": "2026-04-01",
        "summary": "QuidelOrtho Corp (ISIN: US7476011036) is a significant entity in in vitro diagnostics, specializing in point-of-care testing and immunoassay markets. This analysis from early 2026 delves into its business model, competitive landscape, and strategic watchpoints. The company's dual-track approach featuring rapid diagnostics and lab-based assays, along with its focus on recurring revenue from consumables, positions it for continued growth amidst evolving healthcare demands and increasing decentrali",
        "sentiment_score": 0.004216,
        "sentiment_label": "Neutral",
        "relevance_score": 0.339111,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho Corp. Stock Plummets to New 52-Week Low of $14.45",
        "url": "https://www.marketsmojo.com/news/stocks-in-action/quidelortho-corp-stock-plummets-to-new-52-week-low-of-1445-3926327",
        "date": "2026-03-30",
        "summary": "QuidelOrtho Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has hit a new 52-week low of $14.45, marking a significant 64.06% decline in its 1-year performance. The company has faced negative financial results for 12 consecutive quarters, a high debt-equity ratio of 1.31, and a consistent underperformance compared to the S&P 500. This plummet reflects ongoing difficulties and a challenging year for the company.",
        "sentiment_score": -0.800463,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.273,
          "confidence": 0.27
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Vanguard disaggregates holdings; reports 0 shares of QuidelOrtho (QDEL)",
        "url": "https://www.stocktitan.net/sec-filings/QDEL/schedule-13g-a-quidel-ortho-corp-amended-passive-investment-disclosur-44c882a5a324.html",
        "date": "2026-03-28",
        "summary": "Vanguard Group has filed an amended Schedule 13G/A for QuidelOrtho (QDEL), reporting zero beneficial ownership of common stock. This change is due to an internal realignment where certain subsidiaries will now report their ownership separately, as per SEC Release No. 34-39538. Previously, these holdings were aggregated under The Vanguard Group, which now disclaims beneficial ownership of shares held by these subsidiaries.",
        "sentiment_score": 0.003632,
        "sentiment_label": "Neutral",
        "relevance_score": 0.345547,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Precision Trading with Quidelortho Corp Com (QDEL) Risk Zones",
        "url": "https://news.stocktradersdaily.com/news_release/151/Precision_Trading_with_Quidelortho_Corp_Com_QDEL_Risk_Zones_032726103202_1774665122.html",
        "date": "2026-03-27",
        "summary": "This article analyzes Quidelortho Corp Com (QDEL) with a short bias due to weak sentiment across all horizons, indicating a breakdown is underway. It provides three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal analysis, showing weak signals across near-term, mid-term, and long-term horizons, and highlights elevated downside risk.",
        "sentiment_score": -0.64785,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.273,
          "confidence": 0.27
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho Corporation (NASDAQ:QDEL) Given Average Recommendation of \"Reduce\" by Brokerages",
        "url": "https://www.marketbeat.com/instant-alerts/quidelortho-corporation-nasdaqqdel-given-average-recommendation-of-reduce-by-brokerages-2026-03-26/",
        "date": "2026-03-26",
        "summary": "QuidelOrtho Corporation (NASDAQ:QDEL) has received an average \"Reduce\" rating from six brokerages, with a 12-month average price target of $31.50. Despite this, recent insider activity shows the CEO and CFO purchasing shares. The company reported better-than-expected Q4 earnings with revenue up 2.2% year-over-year, but still faces a negative net margin and PE ratio.",
        "sentiment_score": -0.281054,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer",
        "url": "https://www.barchart.com/story/news/914893/nathaniel-sisitsky-joins-quidelortho-as-chief-legal-officer",
        "date": "2026-03-26",
        "summary": "QuidelOrtho Corporation has appointed Nathaniel \"Nate\" Sisitsky as its new Chief Legal Officer, effective March 23, 2026. Sisitsky brings over 25 years of legal and governance experience from the life sciences and technology sectors and previously served as Chief Legal Officer at STAAR Surgical Company. He succeeds Michelle Hodges, who is retiring and will serve in an advisory role for a smooth transition.",
        "sentiment_score": 0.422636,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.128,
          "confidence": 0.13
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Medtech business QuidelOrtho hires STAAR Surgical legal head as CLO",
        "url": "https://www.globallegalpost.com/news/medtech-business-quidelortho-hires-staar-surgical-legal-head-as-clo-312927133",
        "date": "2026-03-25",
        "summary": "QuidelOrtho, a US medtech company, has appointed Nathaniel Sisitsky as its new Chief Legal Officer, succeeding the retiring Michelle Hodges. Sisitsky brings over 25 years of legal experience in life sciences and technology, joining from STAAR Surgical where he also served as CLO. He will be responsible for leading QuidelOrtho's global legal, compliance, and corporate governance functions.",
        "sentiment_score": 0.310766,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.128,
          "confidence": 0.13
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho names Nathaniel Sisitsky as chief legal officer By Investing.com",
        "url": "https://au.investing.com/news/company-news/quidelortho-names-nathaniel-sisitsky-as-chief-legal-officer-93CH-4327018",
        "date": "2026-03-25",
        "summary": "QuidelOrtho Corporation (NASDAQ:QDEL) has appointed Nathaniel Sisitsky as Chief Legal Officer, effective Monday, replacing Michelle Hodges, who is retiring. Sisitsky brings over 25 years of legal and governance experience in life sciences and technology sectors. The appointment comes as QuidelOrtho faces financial challenges, with its shares significantly down and the company carrying substantial debt, though analysts predict a return to profitability this year.",
        "sentiment_score": 0.431162,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.128,
          "confidence": 0.13
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho (QDEL) Welcomes New Chief Legal Officer",
        "url": "https://www.gurufocus.com/news/8737950/quidelortho-qdel-welcomes-new-chief-legal-officer",
        "date": "2026-03-25",
        "summary": "QuidelOrtho (QDEL) has appointed Nathaniel \"Nate\" Sisitsky as its new Chief Legal Officer, effective March 23, to lead the company's global legal, compliance, and corporate governance activities. Sisitsky brings over 25 years of experience in life sciences and technology sectors. Despite this leadership enhancement, the company faces significant financial challenges, including declining revenue, negative profitability margins, high leverage, and a distress-level Altman Z-Score, suggesting potent",
        "sentiment_score": -0.272703,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.494,
          "confidence": 0.49
        }
      },
      {
        "source": "alpha_vantage",
        "title": "In Vitro Diagnostics Firm QuidelOrtho Picks New Legal Chief",
        "url": "https://news.bloomberglaw.com/business-and-practice/in-vitro-diagnostics-firm-quidelortho-picks-new-legal-chief",
        "date": "2026-03-24",
        "summary": "QuidelOrtho Corp., a leader in in vitro diagnostics, has appointed Nathaniel \"Nate\" Sisitsky as its new chief legal officer, effective March 24, 2026. Sisitsky brings over 25 years of legal and governance experience from the life sciences and technology sectors, having previously served as chief legal officer at STAAR Surgical Co. He succeeds Michelle Hodges, who is retiring.",
        "sentiment_score": 0.251719,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.128,
          "confidence": 0.13
        }
      },
      {
        "source": "alpha_vantage",
        "title": "In Vitro Diagnostics Firm QuidelOrtho Picks New Legal Chief",
        "url": "https://news.bloomberglaw.com/in-house-counsel/in-vitro-diagnostics-firm-quidelortho-picks-new-legal-chief",
        "date": "2026-03-24",
        "summary": "QuidelOrtho Corp., a global leader in in vitro diagnostics, has appointed Nathaniel \"Nate\" Sisitsky as its new chief legal officer, effective Monday. Sisitsky brings over 25 years of legal and governance experience, particularly within the life sciences and technology sectors, having most recently served as CLO at STAAR Surgical Co. He succeeds Michelle Hodges, who is retiring.",
        "sentiment_score": 0.10602,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.128,
          "confidence": 0.13
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QuidelOrtho Announces Chief Legal Officer Leadership Transition",
        "url": "https://www.tipranks.com/news/company-announcements/quidelortho-announces-chief-legal-officer-leadership-transition",
        "date": "2026-03-24",
        "summary": "QuidelOrtho (QDEL) has announced a leadership transition for its Chief Legal Officer role. Michelle A. Hodges will retire effective March 23, 2026, and transition into an advisory role for up to 24 months to ensure continuity. Nathaniel “Nate” Sisitsky, a seasoned legal executive with over 25 years of experience in life sciences and medtech, has been appointed as the new Chief Legal Officer and Corporate Secretary.",
        "sentiment_score": 0.035117,
        "sentiment_label": "Neutral",
        "relevance_score": 0.317233,
        "sentiment": {
          "label": "positive",
          "score": 0.128,
          "confidence": 0.13
        }
      },
      {
        "source": "pubmed",
        "pmid": "41964639",
        "title": "Socioeconomic and Behavioral Inequalities in Cardiovascular Health: Insights From a Multiethnic Asian Nation.",
        "authors": "Ang NED et al.",
        "journal": "JACC. Asia",
        "date": "2026 Apr 4",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41964639/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41910522",
        "title": "Excess and Dysfunctional Fat as a Primary Driver of Heart Failure With Preserved Ejection Fraction: From Institutional Recognition to Clinical Integration.",
        "authors": "Packer M et al.",
        "journal": "JACC. Heart failure",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41910522/",
        "sentiment": {
          "label": "positive",
          "score": 0.226,
          "confidence": 0.23
        }
      },
      {
        "source": "pubmed",
        "pmid": "41903165",
        "title": "EMPEROR-Preserved Risk Model and Outcomes in the FINEARTS-HF Trial: A Prespecified Secondary Analysis of FINEARTS-HF.",
        "authors": "Chimura M et al.",
        "journal": "JAMA cardiology",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41903165/",
        "sentiment": {
          "label": "negative",
          "score": -0.473,
          "confidence": 0.47
        }
      },
      {
        "source": "pubmed",
        "pmid": "41740461",
        "title": "The safety, reactogenicity, and immunogenicity of the self-amplifying mRNA COVID-19 vaccine GRT-R910 as a booster in healthy adults.",
        "authors": "Whitaker JA et al.",
        "journal": "Vaccine",
        "date": "2026 Apr 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41740461/",
        "sentiment": {
          "label": "positive",
          "score": 0.67,
          "confidence": 0.67
        }
      },
      {
        "source": "pubmed",
        "pmid": "41674454",
        "title": "Diagnosis of Cardiac Amyloidosis on Echocardiography Using Artificial Intelligence.",
        "authors": "Ioannou A et al.",
        "journal": "Circulation. Cardiovascular imaging",
        "date": "2026-04-22",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41674454/",
        "sentiment": {
          "label": "positive",
          "score": 0.477,
          "confidence": 0.48
        }
      },
      {
        "source": "pubmed",
        "pmid": "41627802",
        "title": "Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial.",
        "authors": "Pop-Busui R et al.",
        "journal": "JAMA internal medicine",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41627802/",
        "sentiment": {
          "label": "positive",
          "score": 0.226,
          "confidence": 0.23
        }
      },
      {
        "source": "sec",
        "filing_type": "8-K",
        "title": "8-K  - Current report",
        "date": "2026-04-15",
        "url": "https://www.sec.gov/Archives/edgar/data/1906324/000190632426000013/0001906324-26-000013-index.htm",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "sec",
        "filing_type": "8-K",
        "title": "8-K  - Current report",
        "date": "2026-03-24",
        "url": "https://www.sec.gov/Archives/edgar/data/1906324/000119312526120684/0001193125-26-120684-index.htm",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      }
    ]
  }
}